Seoul Semiconductor: Everlight Convicted for Stealing World-First Technology
26.8.2025 15:00:00 CEST | Business Wire | Press Release
The Supreme Court of Korea has recently upheld a lower court ruling convicting Taiwan-based Everlight Electronics Co., Ltd. of violating the Act on Prevention and Protection of Industrial Technology for misappropriating Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890)’s patented LED technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826901820/en/
[Table] Summary of Seoul Semiconductor vs. Everlight Lawsuits (Image: Seoul Semiconductor)
Everlight was indicted for bribing three former employees of Seoul Semiconductor to misappropriate core technologies developed over decades of R&D, including the world’s first No-wire second-generation LED technology and advanced UV LED technologies. The former employees who leaked the technologies were also sentenced to prison terms.
Although Everlight initially appealed its first-trial conviction for trade secret infringement, the appellate court determined that Seoul Semiconductor’s technologies went beyond ordinary trade secrets and qualified as advanced national industrial technologies under Korea’s Industrial Technology Protection Act, adding further charges. Last week, the Supreme Court upheld the lower court’s ruling, making the conviction final.
Industry experts view the Supreme Court’s ruling as a meaningful precedent that will foster research and development while advancing the quality of human life. The decision confirms that Korea’s criminal jurisdiction can be effectively applied to foreign companies, and that under the principle of dual liability, both individuals and corporations can be held accountable.
This ruling serves as a strong warning to both domestic and overseas companies attempting to steal technology, either directly or indirectly. At the same time, it is expected to encourage fair competition and creative innovation.
In addition to the technology theft litigation, Seoul Semiconductor has vigorously pursued Everlight’s patent infringements. Over the past seven years, the company has won all 16 patent lawsuits across five countries, securing court orders prohibiting sales and mandating the recall of infringing products. Seoul Semiconductor is closely tracking the enforcement of the rulings and making sure companies aren’t disregarding them to save costs.
Lee Chung-hoon, founder of Seoul Semiconductor and the son of a farmer, stated, “Birth may be unfair, but opportunity must be fair. When intellectual property rights are respected, they give hope to struggling young people and companies, foster creative innovation, and gradually improve people’s lives.”
He further emphasized, “We are determined to dedicate ourselves to research and development, choosing bold failure over mere survival. And we will respond resolutely, even at all costs, against companies that infringe on our patents.”
For the past 30 years, Seoul Semiconductor has dedicated itself to the research and development of optical semiconductors, amassing more than 18,000 patents—an unparalleled portfolio in the LED industry. These are not merely numbers; they include core technologies that define the second generation of the LED industry, such as the world’s first No-wire technology (essential for MicroLED display manufacturing) and the world’s first RGB 1-chip technology. Today, Seoul Semiconductor stands as the world’s No. 1 in LED backlight technology, No. 1 in UV LEDs, and No. 3 in the global LED industry overall, solidifying its position as a leading optical semiconductor company.
About Seoul Semiconductor
Seoul Semiconductor is the world’s third-largest global optoelectronics (LED) company, specializing in LED technology for over 30 years. With the vision of "Making the world clean, healthy, and beautiful through light," Seoul Semiconductor leads a new paradigm of light across various industries, including lighting, automotive, IT (such as backlighting), and its subsidiary, Seoul Viosys, which specializes in MicroLED, UV, Sensors, and Datacomm (SD).
Some of the groundbreaking technologies developed by Seoul Semiconductor include the world’s first innovative No-wire LED technology WICOP, the SunLike LED, which replicates natural sunlight spectrum, the high-voltage LED Acrich, the ultra-bright nPola LED (10 times brighter than conventional LEDs), the RGB one-chip MicroLED WICOP Pixel, and UV sterilization technology Violeds.
Seoul Semiconductor holds an impressive portfolio of over 18,000 patents, and in the last 20 years, the company has won over 100 cases in patent litigation across 8 countries. Believing that the patent system provides hope for young people and serves as a foundation for building a better world, the company is actively engaged in intellectual property protection. For more details, visit our official website (www.seoulsemicon.com or www.seoulviosys.com) and our social media channels (LinkedIn).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250826901820/en/
Contacts
Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom